Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to Wegovy ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

The randomised, multi-centre, placebo-controlled, double-blind, parallel, placebo-controlled trial included 1,032 pre-diabetic individuals. These participants continued treatment for an additional ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

The winner of the first major head-to-head study of weight loss jabs has been revealed. The trial included 751 people from across the U.S. who were overweight or had obesity and at least one other ...